• Home
  • About us
  • Team
    • Management team
    • Advisory Board
  • Portfolio companies
    • Exited investments
    • Current investments
  • News
  • Contact

Not disclosed

Home / Portfolio companies / Exited investments / Not disclosed

An undisclosed investment, this clinical-stage company in the UK is developing a drug against a severe CNS disorder based on research from one of the top universities.

 

News

13
oct

Immusoft and Takeda Collaborate to Discover and Develop Cell Therapies for Rare Neurometabolic Disorders

More
25
jun

Pipeline Therapeutics Appoints Scott Oross as General Counsel

More
23
jun

Immusoft Announces Formation Of Scientific Advisory Board

More